What are all forms of neurofibromatosis, including NF1 (neurofibromatosis type 1), Legius syndrome (SPRED1 disorder), segmental neurofibromatosis, NF‑Noonan syndrome, spinal neurofibromatosis, Watson syndrome, NF2‑related schwannomatosis (neurofibromatosis type 2‑related schwannomatosis), other schwannomatoses, as well as the related RASopathies and tuberous sclerosis complex?

Overview of Neurofibromatosis Forms and Related Conditions

The neurofibromatoses and related conditions comprise a spectrum of distinct genetic disorders affecting the RAS-MAPK pathway, with only NF1 and NF2-related schwannomatosis (formerly called NF2) being well-defined clinical and molecular entities, while other variants including segmental forms, Watson syndrome, NF-Noonan syndrome, spinal neurofibromatosis, schwannomatosis subtypes, RASopathies, and tuberous sclerosis represent separate conditions with overlapping features but distinct genetic etiologies and cancer risks. 1, 2

Well-Defined Neurofibromatosis Entities

Neurofibromatosis Type 1 (NF1)

• Prevalence: 1/2,000 to 1/3,000 births, making it one of the most common cancer predisposition syndromes 1
• Genetics: Autosomal dominant, caused by pathogenic variants in the NF1 gene encoding neurofibromin (negative RAS-MAPK regulator)
• Key features: Café-au-lait macules, neurofibromas, plexiform neurofibromas (50% of patients), optic pathway gliomas (20%), Lisch nodules, bone dysplasia, learning disabilities
• Cancer risks: Age-dependent tumors including optic pathway gliomas (median age 4-5 years), JMML, rhabdomyosarcoma, neuroblastoma in childhood; MPNST, pheochromocytomas, GIST, breast cancer in adults 1
• Diagnostic update: Revised criteria in 2021 specifically differentiate NF1 from Legius syndrome 1

NF2-Related Schwannomatosis (Formerly Neurofibromatosis Type 2)

• Critical nomenclature change: The name "neurofibromatosis type 2" has been officially changed to "NF2-related schwannomatosis" because neurofibromas do NOT occur in this syndrome—the term "neurofibromatosis" is factually incorrect for this condition 2
• Genetics: Caused by NF2 gene mutations
• Key features: Bilateral vestibular schwannomas (hallmark), multiple cranial and spinal nerve schwannomas, meningiomas, ependymomas, intramedullary spinal cord tumors 3, 4
• Distinguishing feature: Schwannomas, not neurofibromas

Mosaic and Segmental Forms

Segmental Neurofibromatosis

• Definition: Localized or regional manifestations of NF1 or NF2 features confined to one body segment
• Mechanism: Somatic mosaicism documented at molecular level for both NF1 and NF2 5, 6
• Clinical presentation: Variable features limited to specific body regions; may have few clinical manifestations 1
• Surveillance: Currently no recommendation to change tumor surveillance based on mosaic status 1

Spinal Neurofibromatosis

• Features: Hereditary form with predominant spinal involvement
• Classification: Recognized as a distinct rare variant 5, 6
• Tumors: Paraspinal peripheral nerve sheath tumors and potential intramedullary spinal cord tumors 4

NF1-Related Syndromes

Watson Syndrome

• Relationship: Overlapping phenotype with NF1
• Features: Café-au-lait macules, pulmonary stenosis, intellectual disability
• Status: Recognized as a distinct clinical entity requiring further delineation 5, 6

NF-Noonan Syndrome (Noonan/Neurofibromatosis Syndrome)

• Features: Overlapping characteristics of both Noonan syndrome and neurofibromatosis
• Status: Requires further clinical delineation; represents phenotypic overlap rather than a single entity 5, 6
• Genetics: Part of the RASopathy spectrum

Legius Syndrome (SPRED1 Disorder)

Legius syndrome is the condition with the most phenotypic overlap with NF1 but critically lacks tumor risk, making accurate differentiation essential for cancer surveillance decisions. 1, 7

• Genetics: Autosomal dominant, caused by SPRED1 pathogenic variants (negative RAS-MAPK regulator)
• Key features: Café-au-lait macules, freckling, lipomas, macrocephaly, learning difficulties
• Critical distinction: NO neurofibromas, NO tumor risk 7
• Surveillance: No cancer surveillance warranted 8
• Diagnostic importance: The 2021 revised NF1 diagnostic criteria specifically focus on differentiating NF1 from Legius syndrome 1

Other Schwannomatosis Subtypes

The 2022 International Consensus Group revised nomenclature recognizes that schwannomatosis encompasses multiple genetic subtypes with overlapping clinical presentations. 2

SMARCB1-Related Schwannomatosis

• Genetics: SMARCB1/INI1 mutations
• Features: Multiple schwannomas without bilateral vestibular involvement
• Presentation: Often presents with pain 3

LZTR1-Related Schwannomatosis

• Genetics: LZTR1 mutations
• Features: Multiple schwannomas, overlapping clinical features with NF2-related schwannomatosis 2

General Schwannomatosis Features

• Phenotype: Limited to multiple schwannomas
• Inheritance: Dominantly inherited with high new mutation rate and variable expression 3

RASopathies (Related Conditions)

All RASopathies except Legius syndrome carry significantly increased cancer risk compared to the general population, requiring specific surveillance protocols. 1, 8

Noonan Syndrome (NS)

• Genetics: PTPN11 (50%), SOS1 (13%), RAF1 (5%), RIT1 (5%), or rarely KRAS, NRAS, BRAF, MAP2K1, RRAS, RASA2, A2ML1, SOS2, LZTR1 8
• Features: Short stature, macrocephaly, congenital heart defects (pulmonary stenosis, hypertrophic cardiomyopathy), dysmorphism, learning difficulties
• Cancer risk: ~8-fold increased risk overall; dysembryoplastic neuroepithelial tumors, ALL, neuroblastoma, rhabdomyosarcoma 8
• High-risk mutations: Specific PTPN11 mutations (especially codon 61 or T73I) and certain KRAS mutations carry high risk of myeloproliferative disorder/JMML requiring surveillance 8
• Surveillance for high-risk mutations: Physical exam with spleen assessment and CBC with differential every 3-6 months from 0-5 years 8

Costello Syndrome (CS)

• Cancer risk: 15% by age 20 years
• Tumor types: Embryonal rhabdomyosarcoma, neuroblastoma, bladder cancer 8
• Surveillance: Physical exam and abdominal/pelvic ultrasound with chest X-ray every 3-4 months from 0-8 to 10 years; annual urinalysis from age 10 years 8

CBL Syndrome

• Cancer risk: High but not precisely defined JMML risk; rarely other neoplasms 8
• Surveillance: Physical exam with spleen assessment and CBC with differential every 3-6 months from 0-5 years 8

Cardiofaciocutaneous Syndrome (CFCS)

• Cancer risk: Low likelihood (<5%); reported cases include ALL, NHL 8
• Surveillance: No routine surveillance; increased awareness and low threshold for investigating new symptoms 8

Tuberous Sclerosis Complex (TSC)

While not a neurofibromatosis or RASopathy, TSC is a distinct tumor predisposition syndrome that can present with overlapping neurological features.

• Genetics: TSC1 or TSC2 mutations (mTOR pathway dysregulation, not RAS-MAPK)
• Key distinction: Different molecular pathway, different tumor spectrum (cortical tubers, subependymal giant cell astrocytomas, renal angiomyolipomas, cardiac rhabdomyomas)
• Not included in RASopathy surveillance guidelines: Requires separate TSC-specific surveillance protocols

Diagnostic Approach and Pitfalls

When NF1 is Suspected but Criteria Not Met

If a patient has features suggestive of NF1 but doesn't meet full clinical criteria and has negative NF1 genetic testing, systematically consider: 1

• Legius syndrome (SPRED1)
• Other mosaic RASopathies (e.g., KRAS)
• CDKN2A-related melanoma-astrocytoma syndrome
• Constitutional mismatch repair deficiency (PMS2, MLH1, MSH2, MSH6)

Critical Surveillance Distinctions

The evidence stratifies conditions into three surveillance categories 8:

Category I - Surveillance Warranted:

• Costello syndrome
• NS with specific high-risk PTPN11 or KRAS mutations
• CBL syndrome

Category II - Baseline Imaging Only:

• Simpson-Golabi-Behmel syndrome (not a RASopathy but mentioned for completeness)

Category III - No Routine Surveillance:

• NS with non-high-risk mutations
• Legius syndrome
• CFCS
• Other low-risk RASopathies

Common Pitfalls to Avoid

1. Calling NF2-related schwannomatosis "neurofibromatosis type 2": Use the updated 2022 nomenclature 2
2. Applying NF1 cancer surveillance to Legius syndrome patients: Legius syndrome has NO tumor risk 8, 7
3. Assuming all RASopathies have the same cancer risk: Risk varies dramatically by specific genetic mutation 8
4. Missing mosaic NF1 or NF2: Somatic mosaicism can present with limited features but still requires surveillance 1
5. Confusing tuberous sclerosis with neurofibromatosis: Different pathway (mTOR vs RAS-MAPK), different tumors, different surveillance